Larvol Delta - Algiax-Pharmaceuticals-Announces-First-Patient-Enrolled-in-Phase-IIa-Multicenter-ProofofConcept-Study-Evaluating-AP325-in-Chronic-Neuropathic-Pain--

laflunimus (AP-325) - Algiax

https://pipelinereview.com/index.php/2020092175949/Small-Molecules/Algiax-Pharmaceuticals-Announces-First-Patient-Enrolled-in-Phase-IIa-Multi-center-Proof-of-Concept-Study-Evaluating-AP-325-in-Chronic-Neuropathic-Pain.html

Sep 21, 2020

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next